Kornimate/medical-research-clean huggingface dataset:
does serum procalcitonin levels predict sepsis in patients undergoing cytoreductive surgery

Conditions: Cytoreductive Surgery

Summary: serum procalcitonin levels will be considerably higher, for a longer period of time, in patients who develop sepsis compared to patients with sirs or those who have an uncomplicated post-surgical recovery. monitoring of serum procalcitonin trends will allow for an earlier diagnosis of, and initiation of treatment for, sepsis compared to current standard icu methods.


Eligibility criteria:
inclusion criteria: * female or male person ≥ 18 years of age * biopsy proven carcinoma * scheduled for cytoreductive surgery, with or without hipec * eastern cooperative oncology group (ecog) performance status (ps) = 0, 1, or 2 * able to give informed consent for protocol participation exclusion criteria: * participants are not able to understand or provide written informed consent * pre-operative anti-inflammatory medication use within 72 hours of their baseline blood draw * pre-operative infection treatment with corticosteroids within 72 hours of their baseline blood draw * immunosuppressive illness other than neoplasm * pregnant or lactating female
sensory processing, postural stability, and selective motor control in children with hemiplegia

Conditions: Cerebral Palsy, Hemiplegic; Sensory Processing Disorder; Postural Balance; Motor Skills Disorders

Summary: the goal of this observational case-control study is to examine the relationship between sensory processing abilities, postural stability, and selective motor control (smc) in children aged 6-10 years with hemiplegic cerebral palsy (cp). the study compares outcomes in children with hemiplegic cp to age-matched typically developing children (tdc). it aims to determine how differences in sensory processing may relate to motor control and balance deficits in this population.

this study investigated the associations between sensory processing abilities, postural stability, and selective voluntary motor control (svmc) in children diagnosed with hemiplegic cerebral palsy (cp), and compared these findings to age-matched typically developing children (tdc). thirty children with hemiplegic cp and thirty tdc aged 6-10 years were recruited based on predefined inclusion and exclusion criteria. children with cp were selected from the outpatient clinic at the faculty of physical therapy, cairo university. the study used validated clinical tools: the child sensory profile 2 (sp2) to assess sensory processing abilities across multiple sensory systems and behavioral domains; the humac balance system to evaluate postural stability through modified clinical tests of sensory integration, center of pressure testing, and limits of stability assessments; the test of arm selective control (tasc) and the selective control assessment of the lower extremity (scale) to evaluate upper and lower limb svmc, respectively. all participants were assessed in a controlled clinical setting, and statistical comparisons were made between the two groups. the study also examined the correlations between sensory profile data and motor/postural outcomes. ethical approval was obtained, and informed consent was secured from all caregivers. the results are intended to provide insights into the interaction between sensory processing and motor control deficits in children with hemiplegia and to support clinicians in tailoring interventions based on sensory-motor integration profiles.

Eligibility criteria:
inclusion criteria: * diagnosis of spastic hemiplegic cerebral palsy * age between 6 and 10 years * gmfcs levels i or ii * modified ashworth scale score of 1 or 1+ (mild spasticity) * ability to follow simple instructions * caregiver with sufficient english language proficiency exclusion criteria: * botulinum toxin injections within the past 6 months * visual or auditory impairments * orthopedic or neurosurgical intervention to limbs or spine * musculoskeletal deformities * history of seizures

Keywords: sensory processing abilities postural stability selective voluntary motor control unilateral cerebral palsy child sensory profile 2
test safety of biodegradable and permanent limus-eluting stents assessed by optical coherence tomography

Conditions: Coronary Heart Disease

Summary: the objective of the study is to assess the superiority of the biodegradable polymer based limus-eluting stent (nobori®) compared with the permanent polymer based everolimus-eluting stent (xience v®) regarding absolute percentage of uncovered stent strut segments.

the mid-term efficacy of drug-eluting stents has been well-established, but there is an ongoing debate on the potential of an increased incidence of late stent thrombosis, particularly after discontinuation of thienopyridine therapy, as well as of delayed onset of restenosis or catch-up phenomenon with permanent polymer-based des. the extent of strut coverage with reduction of exposed thrombogenic material has been shown to be associated with the inflammatory reaction grade and with the incidence of stent thrombosis. the optical coherence tomography (oct) is an intravascular imaging modality based on light. the principle is similar to intravascular ultrasound, but due to the much shorter wave length of light, it offers a much better resolution up to 10µm, enabling the exact determination of strut coverage, neointimal thickness, vessel size, presence of dissections, and even the presence of inflammation.

Eligibility criteria:
inclusion criteria: * patients older than age 18 with ischemic symptoms or evidence of myocardial ischemia in the presence of ≥ 50% stenosis located in native coronary vessels * written, informed consent by the patient or her/his legally-authorized representative for participation in the study * in women with childbearing potential a negative pregnancy test is mandatory exclusion criteria: * lesion length \>16mm requiring a stent length \>18mm * target lesion located in the left main trunk * in-stent restenosis * acute myocardial infarction * malignancies or other comorbid conditions (for example severe liver, renal and pancreatic disease) with life expectancy less than 12 months or that may result in protocol non-compliance * known allergy to the study medications: rapamycin, everolimus, biolimus, stainless steel or cobalt chrome * inability to take dual antiplatelet therapy for at least 6 months * pregnancy (present, suspected or planned) or positive pregnancy test * previous enrollment in this trial * patient's inability to fully cooperate with the study protocol
acupuncture for the treatment of chronic post-chemotherapy fatigue

Conditions: Fatigue

Summary: this is a randomized, placebo controlled study in cancer patients reporting fatigue persisting for at least two months following completion of chemotherapy. subjects will receive 6 weeks of either acupuncture or placebo treatment as a means of evaluating whether acupuncture reduces chronic fatigue after chemotherapy.


Eligibility criteria:
inclusion criteria: * patients age 18-64 diagnosed with a malignancy (solid tumor or hematologic malignancy). * patients must have received chemotherapy. * patients must complain of fatigue following chemotherapy buy not prior to chemotherapy. * at least 60 days must have elapsed between the last chemotherapy infusion and completion of the first baseline questionnaire. * mean baseline fatigue as measured by the brief fatigue inventory must be four or above. exclusion criteria: * anemia, defined as hb\<9 or active treatment for anemia. iron supplementation is allowed as long as the dose has been stable for at least six weeks. * platelets less than 50,000/microliter or an absolute neutrophil count less than 1,000/microliter. * baseline depression score on the hospital anxiety and depression scale of 11 or above, indicating clinical depression. * thyroid disorder, defined as either thyroid stimulating hormone or free t4 out of normal range, is excluded as it is a possible cause of fatigue unrelated to cancer therapy. * surgery under general anesthesia; immunotherapy; radiotherapy; or initiation of hormonal therapy within the three weeks prior to enrollment. * acupuncture in the previous six weeks. * change in use of any of the following drugs in the prior three weeks: opiates, antidepressants (other than selective serotonin reuptake inhibitors \[ssris\])/anxiolytics; or change in use of ssris in the prior six weeks. "change in use" is defined as initiation or cessation of treatment, or change in prescribed dose or regimen: changes in actual amounts of prn medication taken are allowed.

Keywords: cancer fatigue acupuncture
multimodal mr imaging in patients with glioblastoma treated with dendritic cell therapy

Conditions: Malignant Gliomas

Summary: malignant gliomas are aggressive tumours with poor prognosis despite the current multimodal treatment. hence, there is a clear need for new, effective therapies, among which immune therapy has emerged as a promising treatment option. when interpreting follow-up magnetic resonance (mr) examinations, the radiologist is often confronted with images that are difficult to interpret with the conventional anatomical imaging techniques. the difference between tumour relapse and therapy-mediated changes is not always distinctive. in this project, the investigators attempt to characterize the inflammatory response with parameters from advanced mri techniques like mr spectroscopy, mr perfusion imaging and mr-diffusion imaging. these techniques allow characterization of cellular properties like metabolism and tissue structure respectively. doing so, the investigators will monitor disease evolution in order to timely detect treatment failure, thereby allowing appropriate switch in patient management.


Eligibility criteria:
inclusion criteria: \*\*\*\* patients enrolled in the hgg 2003 hgg-immuno 2003 trial patients, older than 3 and younger than 60 years with relapse of high-grade glioma (anaplastic astrocytoma who grade iii or glioblastoma multiforme who grade iv), histologically diagnosed in the first stage of the disease as well as after relapse or relapse of glioma which was grade ii in the first phase but grade iii or iv upon relapse are treated with dendritic cell therapy (immunotherapy) as single treatment approach (no radiotherapy and/or chemotherapy). \*\*\*\* patients enrolled in the hgg 2010 hgg-immuno 2010 trial * prospective double blind placebo controlled randomised clinical trial hgg-2010 for patients with newly diagnosed glioblastoma in which immunotherapy is integrated in the current standard of care (concommitant radiochemotherapy). exclusion criteria: minor age

Keywords: therapy-induced inflammatory response with magnetic resonance imaging
assessment of bleeding symptoms in normal individuals using a comprehensive history phenotyping instrument

Conditions: Bleeding Disorder

Summary: a wide variety of individuals are at risk for bleeding, but even though bleeding symptoms are common it is difficult to compare different people's symptoms. recent research has found that carefully designed surveys can be used to calculate a bleeding score that is useful for diagnosing bleeding disorders, but normal individuals have not been specifically studied in large numbers with a comprehensive survey. whether factors like race, ethnicity, age, sex, aspirin use, and previous trauma and surgery influence bleeding scores is also unknown. the primary goal of this study is to use a comprehensive computerized questionnaire to record the bleeding symptoms of normal individuals and then assess the range and severity of bleeding symptoms in this normal population. secondary goals include determining whether race, ethnicity, age, sex, aspirin use, and previous trauma and surgery correlate with bleeding symptoms.


Eligibility criteria:
inclusion criteria: * at least 18 years of age. * self-assessed as being generally healthy. * self-assessed as being able to accurately read and answer questions in english about their past medical histories. exclusion criteria: * a diagnosis of any disorder of hemostasis. * a diagnosis of any condition associated with an increased risk of bleeding, namely, any current or previous diagnosis of liver or kidney disease, and malignancy requiring treatment within the past year. * use of heparin, low-molecular weight heparins, warfarin, clopidogrel, or other medications with known anticoagulant or anti-platelet properties in the past 30 days. * history, physical, or known laboratory findings suggestive of any other medical or psychological condition that would impair the participant's ability to accurately respond to questions about bleeding symptoms.
study of rhasb in patients with mucopolysaccharidosis vi

Conditions: Mucopolysaccharidosis VI

Summary: the purpose of this study is to evaluate the long-term efficacy and safety of rhasb treatment in patients with mucopolysaccharidosis vi.


Eligibility criteria:
inclusion criteria: * patient consent * patient must have successfully completed study asb-03-05, including having received at least 20 of 24 scheduled weekly infusions and having missed no more then two consecutive infusions * if female of childbearing potential, patient must have a negative pregnancy test exclusion criteria: * pregnant or lactating patient * patient has received an investigational drug within 30 days prior to study enrollment * patient is unwilling or unable to travel to the primary site for periodic assessments
high-risk factors in patients with colorectal polyps a prospective case-control study

Conditions: Colorectal Polyp

Summary: this prospective case-control study aimed to analyze and summarize the high-risk factors and susceptible genes of patients with colorectal polyps. according to these high-risk factors, the investigators developed and validated a prediction model for colorectal polyps to identify high-risk individuals, in order to provide clinical basis for the etiology research and the establishment of effective preventive measures.

a large cohort of eligible participants were included in the analysis, and classified into derivation and validation cohorts at a ratio of 7:3. demographic and clinicopathological characteristics of participants were utilized to develop a prediction model for colorectal polyps. in the derivation cohort, the lasso regression method was applied to filter variables and select the most useful high-risk factors. multivariate logistic regression analysis was used to identify potential predictors and then a prediction model was established. the predictive performance of the model was evaluated with respect to its discrimination, calibration and clinical usefulness.

Eligibility criteria:
inclusion criteria: * subject aged ≥18 and ≤80 years old. subject with complete data on demography and clinicopathology. exclusion criteria: - subject with inflammatory bowel disease, enterophthisis, familial adenomatous polyposis, p-j syndrome and intestinal lymphoma. a history of severe systemic diseases: liver cirrhosis, metabolic syndrome, chronic kidney disease, malignancy. subject taking blood lipid-lowering drugs, hormone or immunosuppressive agents. unwillingness to cooperate with questionnaire survey. lack of complete clinical data for analysis.
multicenter registry study with therapeutic hypothermia after cardiac arrest in japan

Conditions: Cardiac Arrest

Summary: recently, early defibrillation and cardiopulmonary resuscitation (cpr) for sudden onset of cardiac arrest are advancing, however, survival rate is still very low in the world. furthermore, post-cardiac arrest brain injury is a common cause of morbidity and mortality after successful resuscitation which is urgent issue to be solved. therapeutic hypothermia is part of a standardized treatment strategy for comatose survivors of cardiac arrest in the metabolic phase usually about 15 minutes after cardiac arrest. however, the evidences of the efficacy of therapeutic hypothermia are still few. the optimal candidates, temperature, the timing of initiation, the therapeutic windows and the rate for rewarming have not been defined clinically and should be established. the purpose of this research is the improvement in the outcomes for patients with coma after resuscitation from out-of-hospital cardiac arrest using therapeutic hypothermia established from the analysis of multicenter registry data.


Eligibility criteria:
inclusion criteria: * adult patients who remained unconscious after resuscitation from out-of-hospital or inhospital cardiac arrest * presented the stable hemodynamics with drug treatments or mechanical supporting system including iabp or pcps exclusion criteria: * patients with: * pregnancy * acute aortic dissection * pulmonary thromboembolism * drug poisoning * poor daily activity

Keywords: therapeutic hypothermia after cardiac arrest
longitudinal or transverse orientation of ultrasound probe in minimally invasive venous surgery.

Conditions: Varicose Veins; Endovenous Procedures; Venous Access

Summary: longitudinal ultrasound orientation during central venous cannulation has been suggested by a number of radomised studies to offer superior cannulation rates. this technique may offer a simple, safe and cost-neutral step to improve cannulation rates in the widely performed minimally invasive endovenous intervention.

varicose veins are an extremely common disorder and negatively impact on patient quality of life. in recent years minimally invasive venous treatments for varicose veins (mivt) have emerged as an effective alternative to open surgery. it is associated with a reduction in peri-operative morbidity, recovery time and increased quality of life scores when compared with open surgical stripping4. furthermore, mivt is now widely carried out under local anaesthesia. typically, mivt requires cannulation, under ultrasound guidance, of either the great or small saphenous vein in the lower extremity to allow subsequent passage of a venous catheter. this cannulation technique is widely used for venous and arterial cannulation throughout the body. it entails utilising an ultrasound probe in either a longitudinal or transverse orientation (to the target vein) to guide an entry needle into a target vessel. the longitudinal orientation, while unstable, offers better visualisation of the vein when performed accurately. conversely, the transverse approach is very stable with poorer visualisation of the target vessel. as such, no definitve guidance is available to guide treating physicians as to the optimal orientation with a wide variation among practitioners. the cannulation process for mivt is often further challenged by both the small calibre and tendency toward vasospasm of target veins. failure of cannulation may result in greater rates of conversion to open surgery exposing the patient to the the higher rate of morbidity associated with open surgery. more importantly, repeated cannulation results in significant discomfort and hence a reduction in patient satisfaction. longitudinal ultrasound orientation during venous cannulation has been suggested by a number of radomised studies to offer superior cannulation rates of cannulation. this technique may offer a simple, safe and cost-neutral step to improve cannulation rates in the widely performed mivt. the authors propose a blinded randomized controlled study to investigate the effects of ultrasound orietation on cannulation rates in mivt. to test this hypothesis we plan to randomise 100 patients undergoing mivt to either venous cannulation with transverse or longitudinal orientation of the ultrasound probe.

Eligibility criteria:
inclusion criteria: * for minimally invasive venous surgery of the lower limb (clinical-etiology-anatomy-pathophysiology (ceap) classification score 2 of greater) * intervention requiring venous cannulation of axial lower limb vein * full consent * \>18 years * no concomitant deep venous incompetence exclusion criteria: * general anaesthesia
pharmacotyping of pancreatic patient-derived organoids

Conditions: Pancreatic Cancer

Summary: eus-fnb samples will be used for organoid cultures, which will be co-cultured with cancer associated fibroblasts derived from the surrounding stroma of the lesion. the organoid cultures will be used for pharmacotyping using relevant chemotherapeutic agents used in the clinic, and the organoid's response compared with the patient's response.

aim: to use organoids cultured from diagnostic endoscopic ultrasound (eus)-guided fine needle biopsy (fnb) samples from patients with pancreatic ductal adenocarcinoma (pdac) for pharmacotyping. patients will be included at herlev hospital. eus-fnb will be performed using a standard 19 or 22-gauge fnb needle. oncological treatment administration and evaluation of treatment response will be performed by physicians at the department of oncology, herlev hospital as per current standard of care. following eus-fnb procedure, the tissue is immediately transferred to basal medium and epithelial cells as well as cafs released by digestion and epithelial cells cultured in matrigel. following expansion of the organoids and prior to pharmacotyping, next generation sequencing (ngs) analysis will be performed on both the baseline and the organoid sections to validate if the outgrown organoids correspond to the cancer cells from the baseline sample. organoid co-cultures are exposed to six to ten different drug concentrations ranging from 10-12-10-4 m (depending on the individual drug properties). systemic agents and combinations used in the standard clinical practise will be used. computed tomography (ct) scan of the thorax and abdomen are performed at baseline (within 28 days prior to first study drug administration) to assess efficacy of the drugs in patients.

Eligibility criteria:
inclusion criteria: * signed informed consent * histopathological confirmation of pdac and planned standard first-line treatment prior to entering this study or patients suspected of primary locally advanced, non-metastatic pdac based on cross-sectional imaging undergoing diagnostic standard of care (soc) eus-fnb procedure * age \> 18 years and older * life expectancy greater than 3 months * ecog/who performance status (ps) 0-1 * patients must have normal organ and marrow function as defined below: * white blood cell count (wbc) ≥ 3 x 10⁹/l * platelet count ≥ 100 x 10⁹/l * serum bilirubin ≤1.5 x upper limit of normal (uln) (patients with gilbert's syndrome must have a total bilirubin ≤ 50 mmol/l) * pp ≥ 40 or inr ≤ 1.5 * serum creatinine ≤ 1.5 x uln or crcl ≥ 40 ml/min (using the cockcroft-gault formula) exclusion criteria: * contraindications for nurse administered propofol sedation (naps) * contraindications for eus-fnb procedure

Keywords: organoid personalized medicine